---
title: "Weekly Recap | JXR -7.07%, buybacks amid circular delay"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306350916.md"
description: "JXR fell 7.07% this week to HK$2.170, underperforming the Hang Seng Index by about 1.42 percentage points (the index dropped 5.65%). The daily bars show a mostly one-way slide: Monday opened at HK$2.320 and drifted lower, Tuesday saw a small bounce to HK$2.255, then Wednesday and Thursday pushed down again, with Thursday touching a low of HK$2.135 before closing near the week’s bottom. The weekly range was 8."
datetime: "2026-11-21T05:20:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306350916.md)
  - [en](https://longbridge.com/en/news/306350916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306350916.md)
generator: "portal-rs"
---

# Weekly Recap | JXR -7.07%, buybacks amid circular delay

## The Week

JXR fell 7.07% this week to HK$2.170, underperforming the Hang Seng Index by about 1.42 percentage points (the index dropped 5.65%). The daily bars show a mostly one-way slide: Monday opened at HK$2.320 and drifted lower, Tuesday saw a small bounce to HK$2.255, then Wednesday and Thursday pushed down again, with Thursday touching a low of HK$2.135 before closing near the week’s bottom. The weekly range was 8.62%, and average daily volume ran about 24% above its median, suggesting heavier turnover.

## Key Events

The week centred on share buybacks and cancellations. Early Monday the stock climbed over 3%, and that evening the company filed a next-day disclosure return with HKEX on a share buyback. Further filings followed on Tuesday and Wednesday, covering buybacks and cancellations. Friday saw the stock fall nearly 4% in intraday trading, with another next-day return filed after the close disclosing buyback shares for cancellation. On the filings front, the company issued a further delay in dispatch of a circular on Friday evening, in both Chinese and English versions.

## Analyst Ratings

As of 17 November, 14 brokers cover JXR: 9 rate it buy, 2 rate it overweight, 1 rates it hold, and 2 rate it sell. The consensus rating is buy, with a consensus target of HK$3.190, about 47% above the latest price. Targets range from HK$2.221 to HK$4.685, a wide spread. Among 8 comparable companies in the healthcare services industry, JXR ranks 2nd by analyst rating.

## The Week Ahead

The main open thread is the further delay in circular dispatch, with the new timeline yet to be announced. Several consecutive buyback and cancellation disclosures show the company remains active, but the postponed circular adds uncertainty around the underlying transaction. The next scheduled earnings event is the FY2026 annual results on 25 March 2027, with consensus estimates of EPS 0.0855 and revenue around HK$3.36 billion.

## In Short

Broker sentiment leans positive—11 of 14 analysts rate it buy or overweight, and the consensus target sits about 47% above spot—yet the stock still slid with the broader market this week, and the circular delay adds execution uncertainty. Valuation shows a P/E of about 28.8x against a price-to-book of roughly 0.55x. The tension to watch is whether that wide gap between consensus targets and the current price narrows, and whether the buyback-for-cancellation pace continues.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [01951.HK](https://longbridge.com/en/quote/01951.HK.md)

## Related News & Research

- [Jinxin Fertility Files Next-Day HKEX Return Disclosing Share Buyback](https://longbridge.com/en/news/305823985.md)
- [Jinxin Fertility Files Next Day Disclosure Return With HKEX on Share Buyback](https://longbridge.com/en/news/305677960.md)
- [Jinxin Fertility Files Next Day Disclosure Return to HKEX Announcing Share Buyback](https://longbridge.com/en/news/305456859.md)
- [Jinxin Fertility Discloses Share Buyback in HKEX Filing](https://longbridge.com/en/news/305317355.md)
- [Jinxin Fertility Discloses Share Buyback in HKEX Next-Day Return](https://longbridge.com/en/news/305176731.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**